Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsored by: |
Pfizer |
---|---|
Information provided by: | Pfizer |
ClinicalTrials.gov Identifier: | NCT00442845 |
Physicians tend to always use the lowest dose of statins to initiate therapy even in subjects who require large reductions in cholesterol. The study evaluates if selecting the starting dose based on baseline and target LDL-C cholesterol would provide better results (ie proportion of subjects resching target)
Condition | Intervention | Phase |
---|---|---|
Coronary Arteriosclerosis Diabetes Mellitus, Type 2 Cerebrovascular Accident Dyslipidemia Peripheral Vascular Disease |
Drug: Atorvastatin (Lipitor) |
Phase IV |
Study Type: | Interventional |
Study Design: | Treatment, Non-Randomized, Open Label, Dose Comparison, Parallel Assignment, Safety/Efficacy Study |
Official Title: | ACTFAST: Achieve Cholesterol Targets Fast With Atorvastatin Stratified Titration. A Multicenter, Twelve-Week Treatment, Single Step Titration, Open-Label Study Assessing The Percentage Of Dyslipidemic High-Risk Patients Achieving Low Density Lipoprotein Cholesterol (LDL-C) Target With Atorvastatin Starting Doses Of 10 Mg, 20 Mg, 40 Mg, And 80 Mg |
Estimated Enrollment: | 2080 |
Study Start Date: | January 2003 |
Estimated Study Completion Date: | February 2004 |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Study Director: | Pfizer CT.gov Call Center | Pfizer |
Study ID Numbers: | A2581087 |
Study First Received: | February 28, 2007 |
Last Updated: | April 4, 2007 |
ClinicalTrials.gov Identifier: | NCT00442845 History of Changes |
Health Authority: | Canada: Health Canada |
Antimetabolites Cerebral Infarction Myocardial Ischemia Arteriosclerosis Brain Diseases Cerebrovascular Disorders Brain Ischemia Metabolic Disorder Dyslipidemias Arterial Occlusive Diseases Peripheral Vascular Diseases Heart Diseases Metabolic Diseases Antilipemic Agents Stroke |
Diabetes Mellitus Vascular Diseases Endocrine System Diseases Central Nervous System Diseases Anticholesteremic Agents Ischemia Hydroxymethylglutaryl-CoA Reductase Inhibitors Coronary Disease Diabetes Mellitus, Type 2 Endocrinopathy Brain Infarction Infarction Glucose Metabolism Disorders Atorvastatin Coronary Artery Disease |
Antimetabolites Molecular Mechanisms of Pharmacological Action Cerebral Infarction Myocardial Ischemia Arteriosclerosis Brain Diseases Cerebrovascular Disorders Therapeutic Uses Brain Ischemia Cardiovascular Diseases Dyslipidemias Arterial Occlusive Diseases Peripheral Vascular Diseases Heart Diseases Metabolic Diseases |
Antilipemic Agents Stroke Nervous System Diseases Vascular Diseases Diabetes Mellitus Endocrine System Diseases Central Nervous System Diseases Enzyme Inhibitors Anticholesteremic Agents Hydroxymethylglutaryl-CoA Reductase Inhibitors Pharmacologic Actions Coronary Disease Diabetes Mellitus, Type 2 Brain Infarction Glucose Metabolism Disorders |